18F-PSMA-1007 PET/CT显像在前列腺癌生化复发患者诊断中的应用价值  

Application value of 18 F-PSMA-1007 PET/CT imaging in diagnosis of patients with biochemical recurrence of prostate cancer

作　　者：李肖红[1] 张奇洲[1] 秦永德[1] 李毓斌[1] 赵晓佳[1] 刘立水[1] LI Xiaohong;ZHANG Qizhou;QIN Yongde;LI Yubin;ZHAO Xiaojia;LIU Lishui(Department of Nuclear Medicine,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China)

机构地区：[1]新疆医科大学第一附属医院核医学科,乌鲁木齐830054

出　　处：《新疆医科大学学报》2023年第6期741-745,共5页Journal of Xinjiang Medical University

基　　金：新疆维吾尔自治区自然科学基金项目(2019D01C307)。

摘　　要：目的 探讨氟标记的前列腺特异性膜抗原(18F-PSMA-1007)正电子发射断层显像/X线计算机体层显像(PET/CT)在前列腺癌生化复发(BCRPC)患者诊断中的应用价值。方法 回顾性分析80例接受根治性前列腺切除术后BCRPC患者。按血清前列腺特异性抗原(PSA)水平分为4组,各组患者均行18F-PSMA-1007 PET/CT显像,分析18F-PSMA-1007 PET/CT对BCRPC患者复发或者转移的检出率,以及各组患者的前列腺最大标准化摄取值(SUVmax)与PSA水平的关系,评价18F-PSMA-1007 PET/CT显像在BCRPC患者诊断中的应用价值。结果 80例BCRPC患者均为前列腺腺泡腺癌,血清PSA水平0.3~108.3 ng/mL,平均(0.54±0.25)ng/mL,18F-PSMA-1007 PET/CT显像对4组BCRPC患者发生转移或复发检出率分别为75.75%、83.33%、85.71%、100.00%。所有复发或转移灶SUVmax平均值为17.5±5.49。结论18F-PSMA-1007 PET/CT对BCRPC患者临床复发或转移具有很好的早期评估价值和效能,有利于临床精准评估和制定最优的疗法,值得推广应用。Objective To explore the value of fluorine-labeled prostate-specific membrane antigen(18 F-PSMA-1007)positron emission tomography/x-ray computed tomography(PET/CT)in the diagnosis of patients with biochemical recurrence of prostate cancer(BCRPC).Methods Retrospective analysis of 80 patients with BCRPC after undergoing radical prostatectomy.The patients in each group underwent 18 F-PSMA-1007 PET/CT imaging to analyze the detection rate of recurrence or metastasis in BCRPC patients and the relationship between the maximum standardized uptake value(SUVmax)of the prostate and PSA level in each group.The value of 18 F-PSMA-1007 PET/CT imaging in the diagnosis of BCRPC patients were evaluated.Results 80 patients with BCRPC were prostate alveolar adenocarcinoma with serum PSA levels ranging from 0.3 to 108.3 ng/mL,with a mean of(0.54±0.25)ng/mL.The detection rates of metastasis or recurrence in the four groups of the BCRPC patients by 18 F-PSMA-1007 PET/CT imaging were 75.75%,83.33%,85.71%,and 100.00%.The mean value of SUVmax for all recurrence or metastasis was 17.5±5.49.Conclusion 18 F-PSMA-1007 PET/CT has good value and efficacy for early assessment of clinical recurrence or metastasis in patients with BCRPC,which is beneficial for clinical precision assessment and development of optimal therapy,and it will guide the decision of clinical treatment,which is worth promoting the application.

关 键 词：前列腺癌 生化复发 前列腺特异抗原 PET/CT 

分 类 号：R445.6[医药卫生—影像医学与核医学]